8:01 PM
 | 
Oct 27, 2014
 |  BC Extra  |  Clinical News

One-year follow up for uniQure's liver gene therapy

uniQure N.V. (NASDAQ:QURE) reported top-line one-year follow-up data from a completed Phase I study in eight acute intermittent porphyria (AIP) patients receiving varying doses of the company's AMT-021, a recombinant adeno-associated viral (AAV)...

Read the full 155 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >